Suppr超能文献

靶向胶质瘤:揭示Iba1和CD163在胶质母细胞瘤中的作用

TAMing Gliomas: Unraveling the Roles of Iba1 and CD163 in Glioblastoma.

作者信息

Fuse Haneya, Zheng Yuqi, Alzoubi Islam, Graeber Manuel B

机构信息

School of Medicine, Sydney Campus, University of Notre Dame, 160 Oxford Street, Sydney, NSW 2010, Australia.

Ken Parker Brain Tumor Research Laboratories, Brain and Mind Centre, Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2050, Australia.

出版信息

Cancers (Basel). 2025 Apr 26;17(9):1457. doi: 10.3390/cancers17091457.

Abstract

Gliomas, the most common type of primary brain tumor, are a significant cause of morbidity and mortality worldwide. Glioblastoma, a highly malignant subtype, is particularly common, aggressive, and resistant to treatment. The tumor microenvironment (TME) of gliomas, especially glioblastomas, is characterized by a distinct presence of tumor-associated macrophages (TAMs), which densely infiltrate glioblastomas, a hallmark of these tumors. This macrophage population comprises both tissue-resident microglia as well as macrophages derived from the walls of blood vessels and the blood stream. Ionized calcium-binding adapter molecule 1 (Iba1) and CD163 are established cellular markers that enable the identification and functional characterization of these cells within the TME. This review provides an in-depth examination of the roles of Iba1 and CD163 in malignant gliomas, with a focus on TAM activation, migration, and immunomodulatory functions. Additionally, we will discuss how recent advances in AI-enhanced cell identification and visualization techniques have begun to transform the analysis of TAMs, promising unprecedented precision in their characterization and providing new insights into their roles within the TME. Iba1 and CD163 appear to have both unique and shared roles in glioma pathobiology, and both have the potential to be targeted through different molecular and cellular mechanisms. We discuss the therapeutic potential of Iba1 and CD163 based on available preclinical (experimental) and clinical (human tissue-based) evidence.

摘要

神经胶质瘤是最常见的原发性脑肿瘤类型,是全球发病和死亡的重要原因。胶质母细胞瘤是一种高度恶性的亚型,尤为常见、侵袭性强且对治疗具有抗性。神经胶质瘤,尤其是胶质母细胞瘤的肿瘤微环境(TME)的特征是存在大量肿瘤相关巨噬细胞(TAM),这些巨噬细胞密集浸润胶质母细胞瘤,这是这些肿瘤的一个标志。这群巨噬细胞包括组织驻留小胶质细胞以及源自血管壁和血流的巨噬细胞。离子钙结合衔接分子1(Iba1)和CD163是已确定的细胞标志物,可用于在肿瘤微环境中识别这些细胞并对其进行功能表征。本综述深入探讨了Iba和CD163在恶性神经胶质瘤中的作用,重点关注肿瘤相关巨噬细胞的激活、迁移和免疫调节功能。此外,我们将讨论人工智能增强的细胞识别和可视化技术的最新进展如何开始改变对肿瘤相关巨噬细胞的分析,有望以前所未有的精度对其进行表征,并为它们在肿瘤微环境中的作用提供新的见解。Iba1和CD163在神经胶质瘤病理生物学中似乎既有独特作用又有共同作用,并且两者都有可能通过不同的分子和细胞机制成为治疗靶点。我们根据现有的临床前(实验性)和临床(基于人体组织)证据讨论Iba1和CD163的治疗潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1df8/12070867/48c909907b88/cancers-17-01457-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验